No CRS summary available for this bill.
This section amends the Department of Veterans Affairs (VA) national formulary statute to define "non-opioid pain management drug or biological product" (i.e., an FDA-approved, granted, or cleared drug or biological product that reduces postoperative pain or produces postsurgical or regional analgesia without acting on opioid receptors) and requires the VA Secretary to (1) include such products in the VA national formulary no later than one year after they become eligible for temporary additional payment under Medicare's outpatient prospective payment system (42 U.S.C. 1395l(t)(16)(G)) or separate payment under 42 C.F.R. 416.174 (or successor regulation); and (2) include such products in the VA drug standardization list. This section further prohibits use of the Cost of War Toxic Exposures Fund for these requirements and directs implementation no later than 90 days after enactment.